
New study shows TECVAYLI plus DARZALEX FASPRO may normalize survival rates in multiple myeloma patients.
Johnson & Johnson announced data from the Phase 3 MajesTEC-3 trial showing that combining TECVAYLI with DARZALEX FASPRO significantly improves survival in relapsed or refractory multiple myeloma patients. About 87% of treated patients had mortality r...


